Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Cystic Fibrosis
Interventions: Ivacaftor, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 17
States / cities: Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 13 more

Conditions: Non-Squamous Non-Small Cell Lung Cancer, c-MET
Interventions: Standard of Care, Telisotuzumab Adizutecan, Osimertinib (Osi), Cisplatin, Carboplatin, Pemetrexed; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 18
States / cities: Chandler, Arizona • Duarte, California • Irvine, California + 15 more

Conditions: Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma Refractory, Multiple Myeloma in Relapse
Interventions: EZM0414; Drug
Lead sponsor: Epizyme, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 8
States / cities: Duarte, California • East Brunswick, New Jersey • New York, New York + 3 more

Conditions: Cystic Fibrosis
Interventions: ELX/TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 33
States / cities: Tucson, Arizona • Long Beach, California • Palo Alto, California + 28 more

Conditions: Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Stage IV Liver Cancer, Stage IVA Liver Cancer, Stage IVB Liver Cancer, Vascular Thrombosis
Interventions: Computed Tomography, Single Photon Emission Computed Tomography, Technetium Tc-99m Sulfur Colloid; Procedure · Drug
Lead sponsor: University of Washington; Other
Eligibility: 19 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Advanced or Metastatic Solid Tumor
Interventions: Rogaratinib (BAY1163877), Copanlisib (BAY80-6946); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 7
States / cities: Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 4 more

Conditions: Essential Tremor
Interventions: Transcranial Magnetic Stimulation, Sham Transcranial Magnetic Stimulation; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infections, Respiratory Tract
Interventions: GSK1325756 Solution, GSK1325756 Solution Matching Placebo, GSK1325756 Tablet, GSK1325756 Tablet Matching Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Breast Cancer
Interventions: everolimus, abraxane; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 3
States / cities: Camden, New Jersey • Hamilton, New Jersey • New Brunswick, New Jersey

Conditions: Newly Diagnosed Glioblastoma
Interventions: Nivolumab, Relatlimab, TMZ, Radiation Therapy; Drug · Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 3
States / cities: New York, New York • Durham, North Carolina • Houston, Texas

Conditions: Opioid Use Disorder
Interventions: Gender-specific digital intervention (GSDI), Treatment as usual; Behavioral · Other
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Healthy
Interventions: Imlunestrant, Repaglinide, Omeprazole, Dextromethorphan, Quinidine, Rosuvastatin, Digoxin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 3
States / cities: Cypress, California • South Miami, Florida • San Antonio, Texas

Conditions: Loneliness, Quality of Life
Interventions: Volunteering, Life Review; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 60 Years and older
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza A
Interventions: Pimodivir 600 mg, Placebo, SOC Treatment; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 13 Years to 85 Years
Enrollment: 553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 140
States / cities: Birmingham, Alabama • Scottsboro, Alabama • California City, California + 105 more

Conditions: Unresectable Cholangiocarcinoma, Biliary Obstruction, Stent Obstruction, Biliary Stricture
Interventions: Photodynamic Therapy; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 2
States / cities: New York, New York

Conditions: Alzheimer Disease, Dementia, Mild Cognitive Impairment, Peer-bonded Caregiver, Caregiver
Interventions: Drumming session, Music-listening session; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: vorinostat, anastrozole, letrozole, exemestane, positron emission tomography, F-18 16 alpha-fluoroestradiol, fludeoxyglucose F 18, laboratory biomarker analysis; Drug · Procedure · Radiation + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Angiosarcoma, Angiosarcoma, Adult
Interventions: Vusolimogene Oderparepvec (VO), Pembrolizumab; Biological · Drug
Lead sponsor: Varun Monga, MBBS; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Quality of Life, Depression, End Stage Renal Disease, Disability Physical
Interventions: CAPABLE Transplant- Open Label Pilot, CAPABLE Transplant- Randomized Control Trial; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Graft Rejection, Kidney Transplantation, Renal Transplantation
Interventions: Belatacept, Cyclosporine, Mycophenolate mofetil (MMF), Corticosteroids; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 12
States / cities: San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 9 more

Conditions: Metastatic Disease
Interventions: intensity modulated radiation therapy; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: TP53 Y220C Mutation, Advanced Solid Tumors
Interventions: metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet, midazolam hydrochloride syrup, rezatapopt; Drug
Lead sponsor: PMV Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Denver, Colorado • Orlando, Florida • Nashville, Tennessee + 2 more

Conditions: Breast Neoplasms, Breast Cancer, Adenocarcinomas, Metastatic Solid Tumors Characterized by HER2/Neu Expression
Interventions: Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Prostate Cancer
Interventions: JNJ-101556143 Formulation 1, JNJ-101556143 Formulation 2, JNJ-101556143 Formulation 3; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 17
States / cities: Colorado Springs, Colorado • Denver, Colorado • New Haven, Connecticut + 13 more

Search by objective public record fields.

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery

Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors

Transcranial Stimulation for Essential Tremor

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects

Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca

Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab

Women's Opioid Treatment Follow-up Study

A Study of Imlunestrant (LY3484356) in Female Healthy Participants

The Helping Older People Engage Project: Improving Social Well-Being in Later Life

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

Photodynamic Therapy (PDT) Cholangiocarcinoma Registry

Music for Pain and Dementia

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma

CAPABLE Transplant

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

Study Using High-Dose Single Fraction Image-Guided Radiotherapy for Metastatic Lesions to Soft Tissue Masses, Lymph Node, or Bone

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing

Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer